Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Monopar Therapeutics changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 14 | 14 | 0 |
| Shares | 301.4K | 271.4K | −30.0K (−10.0%) |
| Value | $182.2K | $91.7K | −$90.5K (−49.7%) |
New holders (4)
Institutions that held Monopar Therapeutics at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 48,086 | $16.0K | 0.00% |
| Gerber, LLC | 28,005 | $9.53K | 0.01% |
| Virtu Financial LLC | 27,170 | $9.00K | 0.00% |
| Two Sigma Investments, LP | 14,302 | $4.87K | 0.00% |
Sold out (4)
Institutions that held Monopar Therapeutics at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Windsor Advisory Group, LLC | 89,974 | $55.8K |
| Two Sigma Securities, LLC | 24,663 | $15.3K |
| HRT Financial LP | 13,078 | $7.00K |
| JPMorgan Chase & Co | 4 | $2 |